Sight Sciences, Inc. (SGHT Quick QuoteSGHT - Free Report) reported $19.56 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 8.5%. EPS of -$0.23 for the same period compares to -$0.25 a year ago.

The reported revenue represents a surprise of +8.06% over the Zacks Consensus Estimate of $18.11 million. With the consensus EPS estimate being -$0.25, the EPS surprise was +8%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Sight Sciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Dry Eye: $0.33 million versus the two-analyst average estimate of $0.23 million. The reported number represents a year-over-year change of -70.4%.
• Revenue- Surgical Glaucoma: $19.23 million compared to the $17.88 million average estimate based on two analysts. The reported number represents a change of -5% year over year.
• Gross Profit - Dry Eye: $0.13 million versus $0.11 million estimated by two analysts on average.
• Gross Profit - Surgical Glaucoma: $16.46 million versus the two-analyst average estimate of $15.15 million.

View all Key Company Metrics for Sight Sciences here>>>

Shares of Sight Sciences have returned +4.6% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.